lungmap-int-news_0.png

Ryan Hohman, JD, Managing Director, Friends of Cancer Research/ Chair, Lung-MAP Public Affairs Committee: 202.944.6708 or rhohman@focr.org

Wendy Lawton, Communications and Public Relations Manager, SWOG, Lung-MAP Public Affairs Committee: 503.348.8675 or lawtonw@ohsu.edu

Press Releases

Press
29
Feb
2016

Lung-MAP, the most collaborative and comprehensive lung cancer clinical trial active in the U.S., uses a targeted screening approach to match...

Press
10
Mar
2015

On March 4, 2015, the U.S. Food and Drug Administration (FDA) announced that it had approved Opdivo (nivolumab) for the treatment of patients with...

Press
03
Dec
2014

Trial will Close One of Five Trial Sub-Studies: Other four sub-studies of targeted treatments for squamous cell lung cancer will continue to...

Press
23
Jul
2014

Groundbreaking study in squamous cell lung cancer opens at more than a hundred and fifty new locations

Press
16
Jun
2014

Lung-MAP is a multi-drug, multi-arm, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer.